IRLA
IRulya Therapeutics Inc.
IRLA | NASDAQ
$32.80
-$0.15 (-0.46%)
Nov 2, 2026, 9:33 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 142K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -142K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -50.43M | -57.29M | -34.62M | -52.02M | -90.32M | -78.89M |
Interest Income | 1.24M | 2.93M | 3.48M | 1.07M | 620K | 2.04M |
Pretax Income | -80.77M | -56.74M | -31.58M | -51.94M | -89.95M | -76.85M |
Net Income | -83.98M | -56.83M | -31.39M | -51.66M | -89.95M | -76.85M |
Selling & General & Admin | 15.05M | 17.58M | 17.7M | 26.01M | 29.52M | 17.59M |
Research & Development | 35.38M | 18.59M | 9.45M | 25.18M | 60.8M | 61.31M |
Other Expenses | -142K | 21.12M | 7.48M | 825K | n/a | n/a |
Operating Expenses | 50.29M | 57.29M | 34.62M | 52.02M | 90.32M | 78.89M |
Interest Expense | n/a | n/a | n/a | 568K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 50.43M | 57.29M | 34.62M | 52.02M | 90.32M | 78.89M |
Income Tax Expense | 3.21M | 87K | -197K | -284K | n/a | n/a |
Shares Outstanding (Basic) | 250.49K | 216.31K | 186.19K | 167.48K | 148.59K | 145.88K |
Shares Outstanding (Diluted) | 250.49K | 216.31K | 186.19K | 167.48K | 148.59K | 145.88K |
EPS (Basic) | -336 | -262 | -168 | -308 | -606 | -526 |
EPS (Diluted) | -336 | -262 | -168 | -308 | -606 | -526 |
EBITDA | -80.62M | -35.98M | -26.82M | -50.99M | -89.6M | -78.56M |
EBIT | -80.77M | -36.17M | -27.14M | -51.19M | -89.95M | -78.89M |
Depreciation & Amortization | 142K | 186K | 322K | 204K | 344K | 332K |
Add to Watchlist
Select watchlists to add or remove IRLA